Navigation Links
Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
Date:10/21/2011

the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law. 

 



'/>"/>
SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , ... July 01, 2015 , ... Apex Therapeutics announced ... International Convention in Philadelphia, PA. , The presentation took place on Tuesday, ... the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
(Date:6/30/2015)... 2015 R-Japan Co.,Ltd. obtained the license of cell ... Medicine from the Ministry of Health, Labour and Welfare Kinki ... The fact that R- Japan ... from Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, ... provide stem cell manufacturing service to medical institutions. As of ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... a webinar to provide advanced scientific research into new classes of Nanoscale Graphene-based ... energy. Touted as 'the wonder material of the 21st Century' by the ...
(Date:6/30/2015)... Americord Registry, one of the fastest growing cord blood banks ... at Kirkland & Ellis LLP, as the newest member of ...   "We are thrilled about Andrew Horne,s ... , CEO of Americord. "He brings a wealth of knowledge ... growth and vision." Andrew Horne is ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4Americord Registry Announces Andrew Horne as Advisory Board Member 2
... (OTC Bulletin Board: CSBR ), a company ... tumor specific data to enhance the value of oncology ... the management team as the Chief Executive Officer of ... Ronnie Morris will join the management team as President ...
... Oct. 28 Q3 2010 Change on a reported ... 9 months 2010Change on a reported ... sales , €7,821m+5.7% , -1.7% , €22,989m+4.8% , ... €7,377m+8.7% , +6.0%Business EPS(1)€1.89+8.6%-2.3%€5.65+8.7%+6.0% In order to facilitate an understanding ...
... Taking Control of Diabetes: Support World Diabetes Day (14th November 2010) -- LONDON, October 28, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by ...
Cached Biology Technology:Champions Biotechnology Reports Additions to its Management Team 2Champions Biotechnology Reports Additions to its Management Team 3Champions Biotechnology Reports Additions to its Management Team 4Resilient Sales and Business EPS(1) in Q3 2010 2Resilient Sales and Business EPS(1) in Q3 2010 3Resilient Sales and Business EPS(1) in Q3 2010 4Resilient Sales and Business EPS(1) in Q3 2010 5Resilient Sales and Business EPS(1) in Q3 2010 6Resilient Sales and Business EPS(1) in Q3 2010 7Resilient Sales and Business EPS(1) in Q3 2010 8Resilient Sales and Business EPS(1) in Q3 2010 9Resilient Sales and Business EPS(1) in Q3 2010 10Resilient Sales and Business EPS(1) in Q3 2010 11Resilient Sales and Business EPS(1) in Q3 2010 12Resilient Sales and Business EPS(1) in Q3 2010 13Resilient Sales and Business EPS(1) in Q3 2010 14Resilient Sales and Business EPS(1) in Q3 2010 15Resilient Sales and Business EPS(1) in Q3 2010 16Resilient Sales and Business EPS(1) in Q3 2010 17Resilient Sales and Business EPS(1) in Q3 2010 18Resilient Sales and Business EPS(1) in Q3 2010 19Resilient Sales and Business EPS(1) in Q3 2010 20Resilient Sales and Business EPS(1) in Q3 2010 21Resilient Sales and Business EPS(1) in Q3 2010 22Resilient Sales and Business EPS(1) in Q3 2010 23Resilient Sales and Business EPS(1) in Q3 2010 24Resilient Sales and Business EPS(1) in Q3 2010 25Resilient Sales and Business EPS(1) in Q3 2010 26Resilient Sales and Business EPS(1) in Q3 2010 27Resilient Sales and Business EPS(1) in Q3 2010 28Resilient Sales and Business EPS(1) in Q3 2010 29Resilient Sales and Business EPS(1) in Q3 2010 30Resilient Sales and Business EPS(1) in Q3 2010 31Resilient Sales and Business EPS(1) in Q3 2010 32Resilient Sales and Business EPS(1) in Q3 2010 33
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... previously communicated that it will amount to at least 340 ... Due to the rapid increase in market growth and orders ... previously communicated guidance that revenue for 2015 will exceed 1,500 ... amount to approximately 2,200 MSEK. Due to receipt ...
(Date:6/15/2015)... , June 15, 2015 A ... from Telstra reveals the majority of US consumers using mobile ... via biometrics, such as fingerprint and voiceprint, instead of having ... According to Telstra,s " Mobile Identity   -   ... report, with smartphones now the primary channel used by ...
(Date:6/12/2015)... June 12, 2015  Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring, announced ... to electronically capture, analyze and identify participants of ... methods. This system can: ... enrollment and subsequent sign-on process is actually the ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... and other businesses step up efforts to cut waste, ... their products and processes, the number of planet-friendly standards ... creating a sometimes-confusing array of options for "going green." ... prototyped a framework to help organizations of all types ...
... American Naturalist :, , Cuttlefish: From camo to tuxedo in ... can twins tell us about mate choice? For the ... For more information or for photos (where available), contact ... to tuxedo in less than a second Cuttlefish have ...
... NORTHRIDGE, CA (April 26, 2011) Folic acid, an essential ... liquid softgel capsule, is absorbed and available within the body ... according to a study presented in a late breaking session ... formulations, fillers and coatings of vitamin products may affect the ...
Cached Biology News:NIST prototypes framework for evaluating sustainability standards 2Tipsheet for the May issue of the American Naturalist 2Tipsheet for the May issue of the American Naturalist 3Study examines folic acid absorption rates from softgel capsule and standard tablet 2
... is the most thoroughly characterized enzyme available ... its overall utility and efficacy. , Its ... PCR applications. , It is QC ... AmpliTaq DNA Polymerase is a 94 kDa ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
... DNA Polymerase is a versatile and easy-to ... PCR applications. GCpro Taq DNA Polymerase is ... E. coli, containing the DNA polymerase I ... a highly processive 5'-3' DNA polymerase activity. ...
Aspergillus (IgG) Ab EIA Sample Size: 100 l...
Biology Products: